[go: up one dir, main page]

CN111298122B - Pharmaceutical composition for treating small cell lung cancer and application thereof - Google Patents

Pharmaceutical composition for treating small cell lung cancer and application thereof Download PDF

Info

Publication number
CN111298122B
CN111298122B CN201911231857.3A CN201911231857A CN111298122B CN 111298122 B CN111298122 B CN 111298122B CN 201911231857 A CN201911231857 A CN 201911231857A CN 111298122 B CN111298122 B CN 111298122B
Authority
CN
China
Prior art keywords
pharmaceutical composition
lung cancer
small cell
cell lung
administration group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911231857.3A
Other languages
Chinese (zh)
Other versions
CN111298122A (en
Inventor
高原
雒江菡
王福玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbin University of Commerce
Original Assignee
Harbin University of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbin University of Commerce filed Critical Harbin University of Commerce
Priority to CN201911231857.3A priority Critical patent/CN111298122B/en
Publication of CN111298122A publication Critical patent/CN111298122A/en
Application granted granted Critical
Publication of CN111298122B publication Critical patent/CN111298122B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a pharmaceutical composition for treating small cell lung cancer and application thereof, belonging to the field of medicines. Which include lurbinedin and selective NA reuptake inhibitors. The mass ratio of the lurbinectin to the selective NA reuptake inhibitor in the pharmaceutical composition is 1: 0.01-1.

Description

Pharmaceutical composition for treating small cell lung cancer and application thereof
Technical Field
The invention relates to a pharmaceutical composition for treating small cell lung cancer and application thereof, belonging to the field of medicines.
Background
Lung cancer is the first malignant tumor with global morbidity and mortality. In recent years, the incidence and mortality of lung cancer in China have rapidly increased. Lung cancer is classified into non-small cell lung cancer (NSCLC) and Small Cell Lung Cancer (SCLC), with SCLC accounting for about 15-20% of all lung cancers.
SCLC is a systemic disease with a poor prognosis with a 5-year survival rate of less than 5%. At present, the first-line treatment of SCLC generally adopts operation and is mainly assisted by chemotherapy or radiotherapy. The chemotherapy drugs mainly comprise etoposide and cisplatin and irinotecan and cisplatin, and except chemotherapy, patients in a limited period are improved in survival by using a chest radiotherapy department. Survival can also be significantly improved by subjecting patients in a limited period of time to a Prophylactic (PCI) therapy directed at chemotherapy to achieve complete or partial remission.
Unlike NSCLC, SCLC has few new breakthroughs beyond existing chemoradiotherapy treatment methods, and especially has far inferior effect on SCLC compared to NSCLC in terms of targeted drugs and immunotherapy.
Recently, the U.S. Food and Drug Administration (FDA) awards a lurbinactedin (PM1183) orphan drug designation, which has been shown based on studies to have an Objective Remission Rate (ORR) of 39.3% in patients with advanced Small Cell Lung Cancer (SCLC) after chemotherapy, and a median Overall Survival (OS) of 11.8 months in patients. This brings new therapeutic promise to SCLC patients.
lurbinectin is an ecteinascidin derivative which is independently developed by PharmaMar, is an inhibitor of RNA polymerase II, can selectively inhibit a trans-activated RNA polymerase II-mediated transcription process, has no influence on the activities of RNA polymerase I and mitochondrial RNA polymerase, and also has no influence on the normal transcription process of mRNA. RNA polymerase II is often over-activated in the transcription process of tumor cells, and lubrinectedin can distort and die the tumor cells in the mitosis process and finally reduce the cell proliferation. In some types of tumors, tumor cells, which are particularly sensitive to lurbinedin, rely on a high-speed running transcriptional process to support their proliferation. The tumors comprise small cell lung cancer, BRCA1/2 mutant breast cancer, platinum drug-resistant ovarian cancer, sarcoma caused by chromosome translocation and the like.
However, in clinical application, the lurkinectin is found to have a relatively obvious bone marrow suppression effect, so that the search for a lower drug administration amount is the key for drug development around the lurkinectin.
Disclosure of Invention
In a first aspect of the invention, a pharmaceutical composition for the treatment of a tumor comprises a lurbinedin and a selective NA reuptake inhibitor.
In one embodiment of the invention, the mass ratio of lurbinedin to selective NA reuptake inhibitor in the pharmaceutical composition is 1: 0.01-1.
In another embodiment of the invention, the mass ratio of lurbinedin to selective NA reuptake inhibitor in said pharmaceutical composition is 1: 0.01-0.2. In a preferred embodiment, the mass ratio of lurbinedin to selective NA reuptake inhibitor in the pharmaceutical composition is 1: 0.05.
In the present invention, the selective NA reuptake inhibitor is selected from one or more of maprotiline, mianserin and reboxetine.
In yet another embodiment of the invention, the pharmaceutical composition further comprises one or more of etoposide, cisplatin and irinotecan. The mass ratio of the lurbinedin to the selective NA reuptake inhibitor to the cisplatin is 1:0.01-0.2: 0.1-0.5; preferably 1:0.05: 0.3.
The second aspect of the invention provides the application of the pharmaceutical composition in preparing a medicament for treating tumors.
In one embodiment, the tumor is selected from small cell lung cancer, breast cancer, or ovarian cancer. Further, the tumor is preferably small cell lung cancer.
Selective NA reuptake inhibitors can block Norepinephrine (NA) reuptake by the central presynaptic membrane, but cannot block the reuptake effect of 5-hydroxytryptamine (5-HT). Is generally used for treating depression clinically. The invention unexpectedly discovers that when the compound is used together with lurbinedin, the compound generates an obvious synergistic effect on the aspect of treating the small cell lung cancer, and can play a certain role in relieving the mental stress of a patient while realizing the treatment of the cancer.
Detailed Description
The invention may be further understood by reference to the following examples, which illustrate some methods of making or using. However, it is to be understood that these examples do not limit the present invention. Variations of the invention, now known or further developed, are considered to fall within the scope of the invention as described herein and claimed below.
Example 1 screening of Lurbinectedin in combination with antidepressants on a cell model of SCLC
Preparing a cell suspension from small cell lung cancer cell line H446 cells in a logarithmic growth phase by using an RPMI1640 culture medium; cells were diluted to a density of 4X 104Per ml; then, 96-well plates were inoculated, and 200ul of cell suspension was added per well and cultured in an incubator. After 24h of incubation, a grouping experiment was performed:
administration group 1 was supplemented with 5. mu.g/ml of lurbinactedin (final concentration);
dosing group 2 added maprotiline at 0.5ug/ml (final concentration);
in the administration group 3, imipramine (final concentration) was added at 0.5 ug/ml;
the administration group 4 was supplemented with 0.5ug/ml of cloxetine (final concentration);
in the administration group 5, 0.5ug/ml of venlafaxine (final concentration) was added;
dosing group 6 added 5ug/ml lurbinedin +0.5ug/ml maprotiline (final concentration);
in the administration group 7, 5ug/ml of lurbinectin +0.5ug/ml of imipramine (final concentration) was added;
dosing group 8 added 5ug/ml lurbinedin +0.5ug/ml chloricetin (final concentration);
administration group 9 was supplemented with 5ug/ml lurbinedin +0.5ug/ml venlafaxine (final concentration).
The control group was given the same amount of medium, cultured for 24h, and the proliferation inhibition rate of each group of cells was measured by MTT method, the proliferation inhibition rate being (control OD value-administration OD value)/control OD value × 100%
The specific results are as follows:
proliferation inhibition ratio (%)
Administration group 1 45.3±1.9
Administration group 2 3.9±0.7
Administration group 3 11.2±2.4
Administration group 4 8.6±1.8
Administration group 5 5.7±1.1
Administration group 6 67.1±2.2
Administration group 7 56.5±1.6
Administration group 8 49.8±1.4
Administration group 9 51.7±2.1
To screen whether there is a synergistic effect of lurbinactin and an antidepressant in treating SCLC. We screened representative drugs of different antidepressant mechanism pathways, such as the selective NA reuptake inhibitor maprotiline, the tricyclic antidepressant imipramine, the selective 5-HT reuptake inhibitor (SSRI) cloxetine, and the 5-hydroxytryptamine-norepinephrine reuptake inhibitor vindolac, at the same weight ratio. From the results, only imipramine in the antidepressant medicaments has certain effect of inhibiting the proliferation of SCLC cells, and other antidepressant medicaments have no obvious inhibition effect on small cell lung cancer cells when being singly administered. After the antidepressant drug and the lurbinedin are combined, the maprotiline has obvious synergistic effect, and the combination effect of other antidepressant drugs is poor.
Example 2 weight ratio screening of Lurbinectedin in combination with maprotiline on a cell model of SCLC
The test method is the same as that in example 1, the related medicaments with different dosages are added into each group, and the specific results are as follows:
Figure BDA0002303339210000041
Figure BDA0002303339210000051
from the results, the lurbinedin and the maprotiline can generate obvious synergistic effect under different weight ratios, wherein the synergistic effect is most obvious when the ratio is 1: 0.05. In addition, we repeated the above experiments in other small cell lung cancer cell lines H20 and H69, which gave results consistent with those in the H446 cell line, which also fully demonstrates the certainty that lurbinedin and maprotiline produce synergistic effects in treating SCLC.
EXAMPLE 3 Effect of pharmaceutical compositions on mouse Small cell Lung cancer model
Collecting about 20g of C57BL mice, half of each, randomly grouping after feeding for 24H, wherein the mice in the model group and the administration group are subcutaneously inoculated with small cell lung cancer cells H4462X 106In each control group, an equal amount of physiological saline was injected. Administration was started one day after lung cancer cell inoculation, and the control group and the model group were injected with physiological saline, and the administration schedule of the administration group was as follows:
administration group 1: intraperitoneal injection of 2.5mg/kg lurbinedin is carried out once a day;
administration group 2: intraperitoneal injection of 0.125mg/kg maprotiline is carried out once a day;
administration group 3: intraperitoneal injection of 0.75mg/kg cisplatin is carried out once a day;
administration group 4: intraperitoneal injection of 2.5mg/kg lurbinedin and 0.125mg/kg maprotiline is carried out once a day;
administration group 5: intraperitoneal injection of 2.5mg/kg lurbinedin, 0.125mg/kg maprotiline and 0.75mg/kg cis-platinum is carried out once a day;
mice were sacrificed 14 days after continuous administration, tumor bodies of each group of tumor-bearing mice were removed, and tumor growth inhibition rates were calculated after weighing, the inhibition rates being (average tumor weight in model group-average tumor weight in administration group)/average tumor weight in model group × 100%
The results are as follows:
tumor weight (g) Inhibition ratio (%)
Model set 3.31±0.54
Administration group 1 2.44±0.37** 26.4
Administration group 2 3.14±0.43 5.1
Administration group 3 2.91±0.49* 11.9
Administration group 4 1.71±0.33** 48.7
Administration group 5 1.35±0.36** 59.3
This summary merely illustrates some embodiments which are claimed, wherein one or more of the features recited in the claims can be combined with any one or more of the embodiments, and such combined embodiments are also within the scope of the present disclosure as if they were specifically recited in the disclosure.

Claims (4)

1.一种用于治疗肿瘤的药物组合物,其包括lurbinectedin和选择性NA再摄取抑制剂,所述药物组合物中的lurbinectedin和选择性NA再摄取抑制剂的质量比为1:0.01-0.2;所述选择性NA再摄取抑制剂选自马普替林,所述肿瘤选自小细胞肺癌。1. A pharmaceutical composition for treating tumors, comprising lurbinectedin and a selective NA reuptake inhibitor, wherein the mass ratio of lurbinectedin and selective NA reuptake inhibitor in the pharmaceutical composition is 1:0.01-0.2 ; the selective NA reuptake inhibitor is selected from maprotiline, and the tumor is selected from small cell lung cancer. 2.根据权利要求1所述的药物组合物,其特征在于,所述药物组合物还包含顺铂。2. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition further comprises cisplatin. 3.根据权利要求2所述的药物组合物,其特征在于,所述lurbinectedin、选择性NA再摄取抑制剂和顺铂的质量比为1:0.01-0.2:0.1-0.5。3. The pharmaceutical composition according to claim 2, wherein the mass ratio of lurbinectedin, selective NA reuptake inhibitor and cisplatin is 1:0.01-0.2:0.1-0.5. 4.权利要求1-3任一项所述的药物组合物在制备治疗肿瘤药物中的应用,所述肿瘤选自小细胞肺癌。4. Use of the pharmaceutical composition according to any one of claims 1-3 in the preparation of a medicament for treating tumors, wherein the tumor is selected from small cell lung cancer.
CN201911231857.3A 2019-12-04 2019-12-04 Pharmaceutical composition for treating small cell lung cancer and application thereof Active CN111298122B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911231857.3A CN111298122B (en) 2019-12-04 2019-12-04 Pharmaceutical composition for treating small cell lung cancer and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911231857.3A CN111298122B (en) 2019-12-04 2019-12-04 Pharmaceutical composition for treating small cell lung cancer and application thereof

Publications (2)

Publication Number Publication Date
CN111298122A CN111298122A (en) 2020-06-19
CN111298122B true CN111298122B (en) 2021-12-21

Family

ID=71159689

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911231857.3A Active CN111298122B (en) 2019-12-04 2019-12-04 Pharmaceutical composition for treating small cell lung cancer and application thereof

Country Status (1)

Country Link
CN (1) CN111298122B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4578447A1 (en) 2023-12-27 2025-07-02 Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Ercc1-xpf complex inhibitor compounds for use in the treatment of cancer

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293128A (en) 2019-11-21 2022-07-01 Pharma Mar Sa Methods for the treatment of small cell lung cancer using lorbinactadine formulations
TWI855149B (en) * 2020-09-04 2024-09-11 西班牙商瑪製藥股份有限公司 Lurbinectedin combinations
CN113713111A (en) * 2021-10-20 2021-11-30 南华大学附属第一医院 Medicine composition for treating small cell lung cancer and overcoming chemotherapy resistance of small cell lung cancer
CN117838853A (en) * 2023-09-21 2024-04-09 中国人民解放军海军军医大学 Application of maprotiline combined with CTLA4 antibody in the preparation of anti-tumor drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103282037A (en) * 2010-11-12 2013-09-04 法马马有限公司 Combination therapy with an antitumor alkaloid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103282037A (en) * 2010-11-12 2013-09-04 法马马有限公司 Combination therapy with an antitumor alkaloid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PM01183 inhibits myeloid-derived suppressor;Hiromasa Kuroda等;《Immunotherapy》;20170907;805-817 *
去甲肾上腺素对人肺癌细胞株H460增殖、迁移和侵袭能力的影响;龙晓莉等;《中国临床药理学与治疗学》;20141130;1217-1221 *
抑郁发生与肺癌患者生存结局关系的研究进展;李慧媛等;《中南大学学报(医学版)》;20190615;685-691 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4578447A1 (en) 2023-12-27 2025-07-02 Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Ercc1-xpf complex inhibitor compounds for use in the treatment of cancer

Also Published As

Publication number Publication date
CN111298122A (en) 2020-06-19

Similar Documents

Publication Publication Date Title
CN111298122B (en) Pharmaceutical composition for treating small cell lung cancer and application thereof
US12178792B2 (en) Pharmaceutical composition and use thereof in preparing drug for treating tumor multi-drug resistance
JP2017513869A (en) Application of cyclic dinucleotide cGAMP in antitumor
WO2022188491A1 (en) Tumor chemotherapy pharmaceutical composition
TWI547277B (en) Honokiol for the treatment or prevention of bladder cancer growth and metastasis and improve the cachexia new use
CN111558044B (en) Pharmaceutical composition containing sunitinib, and preparation and application thereof
CN104758292B (en) PD-0332991 is preparing the purposes of prevention drug-resistant tumor drug
CN103239464B (en) Application of icarisid II in preparation of sensitizer for chemotherapic medicine
CN112089710B (en) Application of 4-hydroxyisoleucine in preparation of antitumor drugs
CN107583054A (en) Cryptotanshinone pharmaceutical composition and its application in treatment chronic myelocytic leukemia medicine is prepared
CN101152192B (en) Application of 1,3-di-O-galloyl 1-4,6-(S)-HHDP-β-D-glucopyranose in the preparation of antitumor drugs
CN105476996A (en) Application of curcumin and afatinib for combined treatment of non-small cell lung cancer
CN101940569A (en) Pharmaceutical composition containing sorafenib, artemisinin and artemisinin derivatives and application of pharmaceutical composition in preparation of drugs for treating cancers
CN104490942B (en) Application of Phellinus Phellinus as Drug for Treating Tumor
CN114177299B (en) Antitumor pharmaceutical composition containing EZH2 inhibitor and SCD1 inhibitor and application thereof
WO2018125950A1 (en) A combination therapy for treating cancer
CN113663081A (en) Application of Melaleuca and PD-1/PD-L1 inhibitors in the preparation of liver cancer drugs
CN101199534B (en) Anti-tumor function of raw panoxadiol derivative
CN107441076B (en) Combined medicine for treating cancer
CN101152193A (en) Application of 1,3,4-tri-O-galloyl-6-O-caffeoyl-β-D-glucopyranose in the preparation of antitumor drugs
CN112043717B (en) Pharmaceutical composition for treating lung cancer and preparation thereof
CN111632149B (en) Pharmaceutical composition for treating lung cancer and preparation thereof
CN117085135B (en) Use of squalene epoxidase inhibitors in the preparation of drugs for treating endometrial cancer
CN107243079A (en) A kind of pharmaceutical composition containing Rhein and its application in antineoplastic is prepared
Zhang et al. Efficacy of Apatinib Combined with Etoposide for Maintenance Therapy in Extensive Stage Small Cell Lung Cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant